B-intervention	0	8	Physical
I-intervention	9	17	activity
O	18	22	does
O	23	26	not
O	27	32	alter
O	33	42	prolactin
O	43	49	levels
O	50	52	in
O	53	57	post
O	57	58	-
O	58	68	menopausal
O	69	74	women
O	74	75	:
O	76	83	results
O	84	88	from
O	89	90	a
O	91	95	dose
O	95	96	-
O	96	104	response
O	105	115	randomized
O	116	126	controlled
O	127	132	trial
O	132	133	.

O	134	143	Increased
O	144	155	circulating
O	156	162	levels
O	163	165	of
O	166	175	prolactin
O	176	180	have
O	181	185	been
O	186	196	associated
O	197	201	with
O	202	211	increased
O	212	216	risk
O	217	219	of
O	220	224	both
O	225	227	in
O	228	232	situ
O	233	236	and
O	237	245	invasive
O	246	252	breast
O	253	259	cancer
O	259	260	.

O	261	263	We
O	264	276	investigated
O	277	284	whether
O	285	287	or
O	288	291	not
O	292	300	physical
O	301	309	activity
O	310	313	had
O	314	315	a
O	316	320	dose
O	320	321	-
O	321	329	response
O	330	336	effect
O	337	339	in
O	340	348	lowering
O	349	355	plasma
O	356	362	levels
O	363	365	of
O	366	375	prolactin
O	376	378	in
O	379	393	postmenopausal
O	394	399	women
O	399	400	.

B-total-participants	401	405	Four
I-total-participants	406	413	hundred
B-eligibility	414	424	previously
I-eligibility	425	433	inactive
I-eligibility	434	437	but
I-eligibility	438	445	healthy
I-eligibility	446	460	postmenopausal
I-eligibility	461	466	women
O	467	471	aged
B-age	472	474	50
I-age	474	475	-
I-age	475	477	74
I-age	478	483	years
O	484	486	of
O	487	490	age
O	491	495	were
O	496	506	randomized
O	507	509	to
B-control	510	513	150
O	514	516	or
O	517	520	300
O	521	524	min
O	525	528	per
O	529	533	week
O	534	536	of
O	537	544	aerobic
O	545	553	physical
O	554	562	activity
O	563	565	in
O	566	567	a
O	568	572	year
O	572	573	-
O	573	577	long
O	578	590	intervention
O	590	591	.

O	592	601	Prolactin
O	602	605	was
O	606	614	measured
O	615	619	from
O	620	627	fasting
O	628	635	samples
O	636	640	with
O	641	642	a
O	643	649	custom
O	649	650	-
O	650	654	plex
O	655	664	multiplex
O	665	670	assay
O	670	671	.

O	672	673	A
O	674	678	high
O	679	687	compared
O	688	690	to
O	691	699	moderate
O	700	706	volume
O	707	709	of
O	710	718	physical
O	719	727	activity
O	728	731	did
O	732	735	not
O	736	742	reduce
B-outcome	743	749	plasma
I-outcome	750	759	prolactin
I-outcome	760	766	levels
O	767	769	in
O	770	779	intention
O	779	780	-
O	780	782	to
O	782	783	-
O	783	788	treat
O	789	790	(
O	790	799	Treatment
O	800	806	Effect
O	807	812	Ratio
O	813	814	(
O	814	817	TER
O	817	818	)
O	819	820	1
O	820	821	.
O	821	823	00
O	823	824	,
O	825	827	95
O	827	828	%
O	829	839	Confidence
O	840	848	Interval
O	849	850	(
O	850	852	CI
O	852	853	)
O	854	855	0
O	855	856	.
O	856	858	95
O	859	860	-
O	861	862	1
O	862	863	.
O	863	865	06
O	865	866	)
O	867	869	or
O	870	873	per
O	873	874	-
O	874	882	protocol
O	883	891	analyses
O	892	893	(
O	893	896	TER
O	897	898	1
O	898	899	.
O	899	901	02
O	901	902	,
O	903	905	95
O	905	906	%
O	907	909	CI
O	910	911	0
O	911	912	.
O	912	914	93
O	915	916	-
O	917	918	1
O	918	919	.
O	919	921	13
O	921	922	)
O	922	923	.

O	924	926	It
O	927	929	is
O	930	938	unlikely
O	939	943	that
O	944	951	changes
O	952	954	in
O	955	964	prolactin
O	965	971	levels
O	972	979	mediate
O	980	983	the
O	984	991	reduced
B-outcome	992	996	risk
I-outcome	997	999	of
I-outcome	1000	1006	breast
I-outcome	1007	1013	cancer
O	1014	1025	development
O	1026	1028	in
O	1029	1033	post
O	1033	1034	-
O	1034	1044	menopausal
O	1045	1050	women
O	1051	1061	associated
O	1062	1066	with
O	1067	1076	increased
O	1077	1083	levels
O	1084	1086	of
O	1087	1095	physical
O	1096	1104	activity
O	1104	1105	.
O	1106	1120	clinicaltrials
O	1120	1121	.
O	1121	1124	gov
O	1125	1135	identifier
O	1135	1136	:
O	1137	1148	NCT01435005
O	1148	1149	.
